---
title: "Zoetis edges past Q3 revenue estimates, revises FY sales view"
description: "Zoetis reported Q3 2025 revenue of $2.4 billion, slightly below analyst expectations. The company revised its full-year 2025 revenue guidance to $9.400 billion - $9.475 billion, citing broader macro t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264214975.md"
published_at: "2025-11-04T12:09:24.000Z"
---

# Zoetis edges past Q3 revenue estimates, revises FY sales view

> Zoetis reported Q3 2025 revenue of $2.4 billion, slightly below analyst expectations. The company revised its full-year 2025 revenue guidance to $9.400 billion - $9.475 billion, citing broader macro trends. Adjusted net income growth is narrowed to 5.5% - 7.0%, with EPS guidance maintained at $6.30 to $6.40. U.S. revenue decreased 2% but increased 3% organically, while international revenue grew 3% reported and 6% organically. Analysts maintain a "buy" rating, with a median 12-month price target of $192.00, reflecting a potential upside of 24.8%.

)

Overview

-   Zoetis Q3 2025 revenue of $2.4 bln missed analyst expectations
-   Adjusted net income for Q3 2025 grows 9% organically
-   Company revises full year 2025 revenue guidance due to broader macro trends

Outlook

-   Zoetis revises full-year 2025 revenue guidance to $9.400 bln - $9.475 bln
-   Company narrows full-year 2025 adjusted net income growth to 5.5% - 7.0%
-   Zoetis maintains adjusted diluted EPS guidance at $6.30 to $6.40

Result Drivers

-   U.S. SEGMENT - Revenue decreased 2% on reported basis but increased 3% organically, driven by companion animal products and livestock portfolio growth
-   INTERNATIONAL SEGMENT - Revenue increased 3% on reported basis and 6% organically, driven by parasiticides and dermatology products
-   REGULATORY MILESTONES - Achieved significant product approvals and geographic expansions, enhancing growth strategy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $2.40 $2.41

Revenue bln bln (11

Analysts

)

### Q3 EPS $1.63

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 14 “strong buy” or “buy”, 6 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the pharmaceuticals peer group is “buy”
-   Wall Street’s median 12-month price target for Zoetis Inc is $192.00, about 24.8% above its November 3 closing price of $144.35
-   The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [ZTS.US - Zoetis](https://longbridge.com/en/quote/ZTS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 硕腾｜10-K：2025 财年营收 94.67 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275813665.md) |
| 如果硕腾的可转换债券触发条件性转换，将会引发流动性和报告风险 | Zoetis (ZTS) 揭示了与其可转换高级票据相关的流动性风险。如果激活了有条件转换特性，票据持有人可能会转换其票据，这将要求公司以现金结算，这可能会影响其财务实力。此外，会计规则可能要求将这些票据从长期负债重新分类为流动负债，从而影响 | [Link](https://longbridge.com/en/news/275970452.md) |
| 怡安集团｜10-K：2025 财年营收 172 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275945420.md) |
| Couche-Tard 简报：蒙特利尔银行表示公司 “在最近的趋势中略微加快了有机增长” | Couche-Tard 简报：BMO 表示公司 “在近期趋势的基础上，略微加速了有机增长” | [Link](https://longbridge.com/en/news/275778205.md) |
| 硕腾第四季度调整后收益和收入上升；提供 2026 年指导 | 硕腾第四季度调整后收益和收入上升；提供 2026 年指导意见 | [Link](https://longbridge.com/en/news/275757981.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.